ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1969

Prevalence and Predictive Value over 16 Years of Serum Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies in the General Population

Elena Generali1, Natasa Isailovic1, Maria De Santis1, Angela Ceribelli1, Fausto Alborghetti2, Guido Colloredo3, Luisa Porrati2, Torsten Matthias4, Alberto Zucchi2, Giacomo Maria Guidelli1, Marta Caprioli1 and Carlo Selmi1,5, 1Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, 2Bergamo Local Health Authority (ASL), Bergamo, Italy, 3Division of Internal Medicine, San Pietro Hospital, Ponte San Pietro (BG), Italy, 4Aesku.Diagnostics, Wendelsheim, Germany, 5BIOMETRA Department, University of Milan, Milan, Italy

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoantibodies, population studies and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The prevalence of Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies in the general population may vary widely, as RF is present in 0-5% and anti-CCP in 0-9% of healthy controls, but the clinical significance in the general population remains unclear. We determined the prevalence of RF and anti-CCP antibodies in a large sample of the general population and their predictive value over developing rheumatoid arthritis (RA) over 16 years.

Methods: We took advantage of a randomly selected sample of a general population study initiated in 1998 (Isola I, originally including 2,828 subjects; 53% women, age 43±13 years) from a well-defined Northern Italian area. Serum RF and anti-CCP were tested in recent years by ELISA on 2,690 samples and data collected in 2017 (Isola II: 50% women, age 58±13 years). Administrative databases were searched for RA diagnoses occurring between enrollment and May 31st 2017. The risk ratio (RR) was calculated for incident RA cases between subjects exposed and not exposed to RF and anti-CCP antibodies.

Results: RF was positive in 276 (10.2%), while anti-CCP were found in 127 (4.7%) subjects, with the latter at medium-high titer (>30 U/mL) in 25 (0.9%) subjects. Twelve (0.4%) cases of RA were found over 16 years, of which 3 (25%) positive for RF and 5 (41.7%) positive for anti-CCP antibodies, mostly at medium-high titer (4/5, 80%). Only one (8.3%) case of RA was positive both for RF and anti-CCP antibodies. We observed two cases of Sjögren’s syndrome, both positive for RF, while one was positive also for anti-CCP. The risk ratio (RR) of developing RA over 16 years is 3.08 (95% confidence interval – CI – 0.82-11.56, p=0.07) for RF positive subjects and 20.13 (95% CI 5.09-79-52, p<0.001), for anti-CCP antibodies positive subjects, and it increases up to 67.46 (95%CI 16.36-253.98; p<0.001) for medium-high titer anti-CCP antibodies.

Conclusion: We report a high prevalence of RF and anti-CCP in the general population of a Northern Italian region, but only anti-CCP are associated with a significantly increased risk of RA over 16 years.


Disclosure: E. Generali, None; N. Isailovic, None; M. De Santis, None; A. Ceribelli, None; F. Alborghetti, None; G. Colloredo, None; L. Porrati, None; T. Matthias, Aesku Diagnostics, 3; A. Zucchi, None; G. M. Guidelli, None; M. Caprioli, None; C. Selmi, None.

To cite this abstract in AMA style:

Generali E, Isailovic N, De Santis M, Ceribelli A, Alborghetti F, Colloredo G, Porrati L, Matthias T, Zucchi A, Guidelli GM, Caprioli M, Selmi C. Prevalence and Predictive Value over 16 Years of Serum Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies in the General Population [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/prevalence-and-predictive-value-over-16-years-of-serum-rheumatoid-factor-and-anti-cyclic-citrullinated-peptide-antibodies-in-the-general-population/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-predictive-value-over-16-years-of-serum-rheumatoid-factor-and-anti-cyclic-citrullinated-peptide-antibodies-in-the-general-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology